1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
General Biologicals Corp.

General Biologicals Corp.

TTPEX:4117
7.30
TWD
+0.30
(+4.29%)
814.11MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.11
5.59
4.67
5.08
4.89
6.17
5.87
8.73
8.92
5.99
4.28
4.07
3.45
- -
Basic EPS, GAAP
0.23
-0.87
-2.27
-2.37
-2.11
-1.75
-0.96
1.14
0.71
-0.86
-3.22
-3.57
7.46
- -
Free Cash Flow per Basic Share
0.86
-1.47
-2.24
-2.62
-1.76
-1.32
-0.12
0.38
-1.39
-0.38
-3.22
-27.68
-4.85
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
10.34
9.5
7.22
4.29
4.04
2.49
1.74
11.07
11.83
11.17
8.01
4.53
12.29
11.25
Tangible Book Value per Share
9.5
8.75
5.52
3.1
2.62
1.68
1.16
10.06
10.77
10.17
7.09
3.66
11.56
10.58
Basic Weighted Avg Shares
27
36
36
36
38
40
41
55
62
62
62
62
62
66
Sales/Revenue/Turnover
195
199
168
185
188
244
240
476
552
370
265
252
216
- -
Operating Margin (%)
-0.79
-15.44
-49.6
-49.47
-48.13
-21.82
-15.79
13.26
5.08
-12.03
-65.63
-84.61
-101.22
- -
Depreciation Expense
19
20
25
29
21
26
32
31
36
36
37
38
79
- -
Net Income, GAAP
6
-31
-82
-86
-81
-69
-39
62
44
-53
-199
-221
466
- -
Effective Tax Rate (%)
35.78
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
8.05
- -
Profit Margin (%)
3.29
-15.5
-48.68
-46.72
-43.29
-28.39
-16.29
13.06
8
-14.36
-75.08
-87.65
215.93
- -
Working Capital
283
236
139
49
31
4
-8
524
433
453
-627
61
396
286
LT Debt
- -
- -
- -
- -
17
26
72
51
438
452
379
2,101
2,369
2,347
Total Equity
357
340
261
180
164
100
72
688
735
693
497
286
872
798
Return on Invested Capital (%)
-0.36
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-6.76
- -
Return on Capital (%)
3.44
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
16.26
- -
Return on Common Equity (%)
2.44
-8.73
-27.21
-39.11
-47.24
-52.47
-45.46
16.43
6.23
-7.48
-33.54
-56.64
80.65
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
137
127
184
LT Borrowings
1,982
1,966
1,940
LT Finance Leases
397
402
407
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
63
71
71
Market Capitalization
1,039
910
814

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
437
793
786
Cash, Cash Equivalents & STI
196
635
604
Accounts Receivable, Net
55
68
86
Inventories
72
59
54
Total Current Liabilities
330
397
501
Payables & Accruals
- -
- -
- -
ST Debt
137
127
184
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
88.49%
27.01%
204.54%
Free Cash Flow
19.59%
167.25%
-82.31%
Net Income, GAAP
-59.33%
-55.12%
-310.96%
Sales/Revenue/Turnover
7.38%
-12.93%
-14.36%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
252
2025
- -
- -
216
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-3.57
2025
- -
- -
7.46
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Meng Te Lin
Full Time Employees
200
Sector
Health technology
Industry
Medical specialties
Address
No. 6, Innovation First Road Hsinchu Taiwan 300092
IPO Date
Jul 4, 2002
Website
gbc.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
General Biologicals Corporation (TWSE: 4117), founded in 1984 and headquartered in Hsinchu Science-Based Park, Taiwan, develops, manufactures and markets in-vitro diagnostics, precision medicine solutions, biopharmaceuticals and consumer healthcare products serving hospitals, laboratories, blood banks and clinics in over 40 countries across Asia, North America, the Middle East and South America. Its core offerings encompass immunoassay technologies including ELISA and chemiluminescence immunoassay (CLIA) systems such as the CL i120 analyzer and reagents for infectious diseases, hepatitis (A/B/C/D), HIV blood screening, tumor markers, thyroid function, hormones, cytokines, cardiac biomarkers and fertility testing; molecular diagnostics via the GBC AIO M160 all-in-one nucleic acid extraction, amplification and analysis platform with RealQuant kits for HBV, HCV and HPV; liquid biopsy technologies under the CellBio brand featuring iFiltration systems like FX10 and a2000 for circulating tumor cell (CTC) detection, monitoring and oncology applications; contract development and manufacturing organization (CDMO) services; blood screening and biomaterial solutions including antibodies and antigens; and P113 antimicrobial peptide pharmaceuticals for oral candidiasis, gingivitis and consumer products under the oh care brand covering oral care, feminine hygiene, baby care, skin care and pet applications. Subsidiaries and affiliates include CurieMed for diagnostic services in Taiwan, Danner Laboratory in the USA for clinical testing, Pacgen Life Science in Canada, GB GENES and DGBC in China. Recent developments feature the May 2025 commissioning of the GBC AI Biotech Building in Hsinchu's AI Smart Park as a hub for nine specialized centers in molecular diagnostics, precision medicine, protein drug R&D, stem cell culture and AI-driven digital pathology; TFDA approval and EU IVDR pursuit for the CL i120 CLIA analyzer driving equipment-plus-reagent sales; multiple CellBio awards including 2025 Taiwan Excellence, SNQ National Quality and National Pharmaceutical Technology Bronze; a three-year exclusive distribution deal with a Brazilian partner for ELISA, CLIA, PCR and hepatitis assays targeting South American blood centers and labs; expanded Fubon Life Insurance CTC testing collaboration exceeding 25,000 cases; and U.S. market launch of CellBio CTC products at AACC 2023 with ongoing global exhibitions.